Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | SENIOR VP, HEAD OF CMC | February 01, 2021 | February 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vistagen Therapeutics, Inc.
Report date February 01, 2021 · Filed February 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-02-01 | Direct | 200,000 |
Reported balance
After 2021-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-01 · Grant · Acquired 200,000 · Balance 200,000 F1: Twenty-five percent (25%) of the shares vest on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter over a period of three (3) years, becoming fully vested on February 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares vest on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter over a period of three (3) years, becoming fully vested on February 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2021 Filed Feb 2, 2021 22:17 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-21-000508 · form4-02022021_020242.xml · derivative · entry 1 Ginski Mark J · CIK 0001843460 · SENIOR VP, HEAD OF CMC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares vest on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter over a period of three (3) years, becoming fully vested on February 1, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.